HOME >> MEDICINE >> NEWS
Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma

LOS ANGELES -- Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells. The complete findings are also available online in Blood.

"There were a number of fascinating findings," says Keith Bible, M.D., Ph.D., oncologist and the studys primary investigator. "In addition to observing many favorable aspects of chaetocin, we discovered some avenues for further research into other possible anti-myeloma agents."

Multiple myeloma is an incurable bone marrow cancer that kills more than 11,000 people each year in the United States, reports the American Cancer Society. Dr. Bibles team has shown for the first time that chaetocin has promising anti-myeloma activity. They found that chaetocins promise includes the ability to:

  • Kill myeloma cells harboring a diverse array of genetic abnormalities
  • Cause biological changes and induce oxidative stress in myeloma cells, leading to their death
  • Selectively kill myeloma cells with superior efficacy to commonly-used anti-myeloma drugs including dexamethasone and doxorubicin
  • Reduce myeloma growth in mice
  • Rapidly accumulate in cancer cells

The researchers were surprised that chaetocin, while structurally similar to anti-cancer agents known as histone deacetylase inhibitors (HDACIs), did not, at cytotoxic concentrations, seem to function as an HDACI; but instead that the cytotoxic mechanism appeared to be at least in part attributable to oxidative stress caused by chaetocin.

"Much more research needs to be done," says Jennifer Tibodeau, Mayo post-doctorate fellow and presenter of the study, "but we are hopeful that chaetocin may some day provide ne
'"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
15-Apr-2007


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
7. Elsevier launches the Clinics on ScienceDirect
8. Clinical guidelines for blood conservation during cardiac procedures developed
9. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
10. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
11. Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... ... September 26, 2017 , ... Ron Norman, CEO of ... use the Law of Large Numbers in favor of senior, upper-level executive job candidates ... casinos, have long understood the Law of Large Numbers as a way of protecting ...
(Date:9/26/2017)... ... September 26, 2017 , ... CGL Electronic Security Inc., an ... its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, LLC office is ... and Jon McCormack, both of whom have creative business development methods, who are responsive ...
(Date:9/26/2017)... Galloway, N.J. (PRWEB) , ... September 26, 2017 ... ... mocktail at the shore, the John R. Elliott HERO Campaign for Designated Drivers ... Hotel & Golf Club. , Thirty-one local bars and restaurants took on the ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Founded as ... decades growing into an innovative leader in special education. In 2018, Glenholme will ... , Glenholme, formerly a world renowned horse farm for Hackney show ponies, was generously ...
(Date:9/26/2017)... ... September 26, 2017 , ... The 2017 American Academy of Cosmetic Surgery ... Fat,” revealed not only the latest about cosmetic procedures to remove and replace fat, ... cosmetic medicine. , “Fat really is magical, especially when it comes to the cosmetic ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Sapheneia and Scannerside received FDA 510(k) clearance ... a third-party Vendor neutral CT product that makes it ... with current MITA standards. ... is specifically designed to provide CT operators, prior to ... over a predefined threshold. Scannerside Dose Check is intended ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a leading ... a vibrant charitable donation program -- "Color for ... congenital heart defect research by The Children,s Heart ... the general public are encouraged to download a ... the completed artwork to the gallery on the ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology:
Cached News: